Cytokines are markers of the Clostridium difficile-induced inflammatory response and predict disease severity

Clinical and Vaccine Immunology

Volumn 24, Issue 8, 2017, Pages

  Yu, Hua ^a   Chen, Kevin ^a   Sun, Ying ^a   Carter, Mihaela ^b   Garey, Kevin W ^c   Savidge, Tor C ^d,e   Devaraj, Sridevi ^d,e   Tessier, Mary Elizabeth ^e   Von Rosenvinge, Erik C ^b   Kelly, Ciaran P ^f   Pasetti, Marcela F ^b   Feng, Hanping ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clostridium difficile infection; Cytokine response; Disease severity; Glucosyltransferase activity

Indexed keywords

BETA INTERFERON; BIOCHEMICAL MARKER; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYTOKINE; GAMMA INTERFERON; GLUCOSYLTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE SEVERITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; PEPTOCLOSTRIDIUM DIFFICILE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TH17 CELL; UPREGULATION;

EID: 85027219071     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00037-17     Document Type: Article

References (51)

1. Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X, Kelly CP, Targan SR, Pothoulakis C. 2013. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother 57:3214–3223. https://doi.org/10.1128/AAC.02633-12.
2. Carter GP, Rood JI, Lyras D. 2010. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 1:58–64. https://doi.org/10.4161/gmic.1.1.10768.
3. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526–536. https://doi.org/10.1038/nrmicro2164.
4. Olson A, Diebel LN, Liberati DM. 2013. Effect of host defenses on Clostridium difficile toxin-induced intestinal barrier injury. J Trauma Acute Care Surg 74:983–989. https://doi.org/10.1097/TA.0b013e3182858477.
5. Madan R, Guo X, Naylor C, Buonomo EL, Mackay D, Noor Z, Concannon P, Scully KW, Pramoonjago P, Kolling GL, Warren CA, Duggal P, Petri WA, Jr. 2014. Role of leptin-mediated colonic inflammation in defense against Clostridium difficile colitis. Infect Immun 82:341–349. https://doi.org/10.1128/IAI.00972-13.
6. Kelly CP, Kyne L. 2011. The host immune response to Clostridium difficile. J Med Microbiol 60:1070–1079. https://doi.org/10.1099/jmm.0.030015-0.
7. El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. 2013. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56: 1713–1721. https://doi.org/10.1093/cid/cit147.
8. Kim H, Kokkotou E, Na X, Rhee SH, Moyer MP, Pothoulakis C, Lamont JT. 2005. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 129:1875–1888. https://doi.org/10 .1053/j.gastro.2005.09.011.
9. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2:326–234. https://doi.org/10.4161/gmic.19142.
10. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Contrl Hosp Epidemiol 31:431– 455. https://doi.org/10.1086/651706.
11. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302–307. https://doi.org/10.1086/519265.
12. Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, Rees R, Taylor B, Wood E, Malakun R. 2011. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 9:CD004610.
13. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586–1590. https://doi.org/10.1086/430311.
14. Czepiel J, Biesiada G, Brzozowski T, Ptak-Belowska A, Perucki W, Birczynska M, Jurczyszyn A, Strzalka M, Targosz A, Garlicki A. 2014. The role of local systemic cytokines in patients infected with Clostridium difficile. J Physiol Pharmacol 65:695–703.
15. Cowardin CA, Kuehne SA, Buonomo EL, Marie CS, Minton NP, Petri WA, Jr. 2015. Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile. mBio 6:e02386-14. https://doi.org/10.1128/mBio.02386-14.
16. Lee JY, Park HR, Oh YK, Kim YJ, Youn J, Han JS, Kim JM. 2007. Effects of transcription factor activator protein-1 on interleukin-8 expression and enteritis in response to Clostridium difficile toxin A. J Mol Med 85: 1393–1404. https://doi.org/10.1007/s00109-007-0237-7.
17. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, Qaman A, Pothoulakis C, LaMont JT, Kelly CP. 2000. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Investig 105:1147–1156. https://doi.org/10.1172/JCI7545.
18. Jefferson KK, Smith MF, Jr, Bobak DA. 1999. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced upregulation and secretion of IL-8 from human monocytes. J Immunol 163:5183–5191.
19. Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ. 2006. NF-kappa B activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scand J Immunol 63: 453– 460. https://doi.org/10.1111/j.1365-3083.2006.001756.x.
20. Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, Dupont HL. 2010. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 51:1406 –1410. https://doi.org/10.1086/657398.
21. Jiang ZD, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M. 2006. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol 101:1112–1116. https://doi.org/10.1111/j.1572-0241.2006.00482.x.
22. Steel JC, Waldmann TA, Morris JC. 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 33:35–41. https://doi.org/10.1016/j.tips.2011.09.004.
23. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H. 1994. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci U S A 91:5109–5113. https://doi.org/10.1073/pnas.91.11.5109.
24. Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates AC, Lamont JT, Kelly CP. 1997. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol 273:G13.
25. Branka JE, Vallette G, Jarry A, Bou-Hanna C, Lemarre P, Van PN, Laboisse CL. 1997. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 112:1887. https://doi.org/10.1053/gast.1997.v112.pm9178681.
26. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. 1996. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 38: 337. https://doi.org/10.1136/gut.38.3.337.
27. Liu Z, Geboes K, Colpaert S, D’Haens GR, Rutgeerts P, Ceuppens JL. 2000. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 164:3608–3615. https://doi.org/10.4049/jimmunol.164.7.3608.
28. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. 2001. Increased expression of IL-16 in inflammatory bowel disease. Gut 48:326–332. https://doi.org/10.1136/gut.48.3.326.
29. Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau KO, Brazer W, Kelly CP. 2000. Interleukin 16 is up-regulated in Crohn’s disease and participates in TNBS colitis in mice. Gastroenterology 119:972–982. https://doi.org/10.1053/gast.2000.18164.
30. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 4:719–722.
31. Ishida Y, Maegawa T, Kondo T, Kimura A, Iwakura Y, Nakamura S, Mukaida N. 2004. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J Immunol 172:3018–3025. https://doi.org/10.4049/jimmunol.172.5.3018.
32. Pawlowski SW, Calabrese G, Kolling GL, Platts-Mills J, Freire R, Alcantara Warren C, Liu B, Sartor RB, Guerrant RL. 2010. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/ NAP1 strain. J Infect Dis 202:1708 –1712. https://doi.org/10.1086/657086.
33. Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N Engl J Med 330:257–262. https://doi.org/10.1056/NEJM199401273300406.
34. Mitchell TJ, Ketley JM, Haslam SC, Stephen J, Burdon DW, Candy DC, Daniel R. 1986. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut 27:78–85. https://doi.org/10.1136/gut.27.1.78.
35. Libby JM, Jortner BS, Wilkins TD. 1982. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun 36:822–829.
36. Lonnroth I, Lange S. 1983. Toxin A of Clostridium difficile: production, purification and effect in mouse intestine. Acta Pathol Microbiol Immunol Scand B 91:395–400.
37. von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M. 1996. Large clostridial cytotoxins–a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol 4:375–382. https://doi.org/10.1016/0966-842X(96)10061-5.
38. Lee JY, Kim H, Cha MY, Park HG, Kim YJ, Kim IY, Kim JM. 2009. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappa B signaling pathway. J Mol Med (Berlin) 87:169 –180. https://doi.org/10.1007/s00109-008-0415-2.
39. Rocha MF, Maia ME, Bezerra LR, Lyerly DM, Guerrant RL, Ribeiro RA, Lima AA. 1997. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun 65:2740–2746.
40. Cowardin CA, Jackman BM, Noor Z, Burgess SL, Feig AL, Petri WA, Jr. 2016. Glucosylation drives the innate inflammatory response to Clostridium difficile toxin A. Infect Immun 84:2317–2323. https://doi.org/10.1128/IAI.00327-16.
41. Ryder AB, Huang Y, Li H, Zheng M, Wang X, Stratton CW, Xu X, Tang YW. 2010. Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system. J Clin Microbiol 48:4129–4134. https://doi.org/10.1128/JCM.01104-10.
42. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247–263. https://doi.org/10.1128/CMR.18.2.247-263.2005.
43. Yang Z, Zhang Y, Huang T, Feng H. 2015. Glucosyltransferase activity of Clostridium difficile toxin B is essential for disease pathogenesis. Gut Microbes 6:221–224. https://doi.org/10.1080/19490976.2015.1062965.
44. Kim MN, Koh SJ, Kim JM, Im JP, Jung HC, Kim JS. 2014. Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice. World J Gastroenterol 20:17084 –17091. https://doi.org/10.3748/wjg.v20.i45.17084.
45. Xu H, Yang J, Gao W, Li L, Li P, Zhang L, Gong YN, Peng X, Xi JJ, Chen S, Wang F, Shao F. 2014. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513:237–241. https://doi.org/10.1038/nature13449.
46. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, Schenck LP, Vilaysane A, Seamone ME, Feng H, Armstrong GD, Tschopp J, Macdonald JA, Muruve DA, Beck PL. 2010. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139:542–552. https://doi.org/10.1053/j.gastro.2010.04.005.
47. Madan R, Petri WA, Jr. 2012. Immune responses to Clostridium difficile infection. Trends Mol Med 18:658–666. https://doi.org/10.1016/j.molmed.2012.09.005.
48. Hansen A, Alston L, Tulk SE, Schenck LP, Grassie ME, Alhassan BF, Veermalla AT, Al-Bashir S, Gendron FP, Altier C, MacDonald JA, Beck PL, Hirota SA. 2013. The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelia barrier dysfunction. PLoS One 8:e81491. https://doi.org/10.1371/journal.pone.0081491.
49. Yang G, Zhou B, Wang J, He X, Sun X, Nie W, Tzipori S, Feng H. 2008. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 8:192. https://doi.org/10.1186/1471-2180-8-192.
50. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, Savidge T, Feng H. 2012. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 80:2679–2688. https://doi.org/10.1128/IAI.00215-12.
51. Katial RK, Sachanandani D, Pinney C, Lieberman MM. 1998. Cytokine production in cell culture by peripheral blood mononuclear cells from immunocompetent host. Clin Diagn Lab Immunol 5:78–81.